NIKKEI 225
38,923.03 +435.13 (+1.13%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.27 -2.72 (-3.53%) GOLD FUTURES
2,362.50 +16.70 (+0.71%) DOW
38,282.98 -403.34 (-1.04%) Bitcoin GBP
54,040.29 +778.05 (+1.46%)
4D Molecular Therapeutics, Inc. (FDMT)
| Previous close | 23.97 |
| Open | 24.37 |
| Bid | 23.69 x 100 |
| Ask | 23.99 x 100 |
| Day's range | 23.80 - 25.40 |
| 52-week range | 9.44 - 36.25 |
| Volume | |
| Avg. volume | 601,244 |
| Market cap | 1.233B |
| Beta (5Y monthly) | 2.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in June. Members of the management team will also be available for one-on-one meetings. Jefferies Global Healthcare Conference Presentation
- GlobeNewswire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic Fibrosis Conference on Thursday, June 6, 2024 at 5:00 p.m. BSTCompany to host webcast on Thursday, June 6, 2024 at 8:00 a.m. ET EMERYVILLE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic
- GlobeNewswire
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3 expected by Q1 2025Interim 24-week landmark analysis from PRISM Phase 2 Population Extension cohort evaluating 4D-150 in broader wet AMD population expected to be presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting on July 17-20, 2024Interim clinical data from Ph
